Welcome To Mylan Inc.

A Legacy You Can Count On

Mylan is the third-largest generic pharmaceutical company in the world. We hold top-five positions in 13 different established markets worldwide and are building a strong presence in many emerging generics markets.

Today, we market more than 570 products to consumers in more than 140 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. We also have the deepest pipeline and largest number of products pending regulatory approval in company history.

At Mylan, we are always ready to meet the challenges of the dynamic global pharmaceutical industry with its numerous and wide-ranging issues – from complex research, development and regulatory conditions to rapidly changing consumer demands.

Whether we’re improving the health of patients worldwide or meeting the diverse needs of our customers, Mylan delivers. Every time, all the time.

More About Mylan

If you have difficulty finding the information you are looking for, please contact us, and we will personally help you with your request.

11/18/2008 - Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem® Pulvules® Capsules... (more)
11/17/2008 - Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR®... (more)
11/06/2008 - Mylan's Dey L.P. Announces Establishment of 'J-Code' for Perforomist™ Inhalation Solution... (more)
11/04/2008 - Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra® and Launches Immediately... (more)
10/30/2008 - Mylan Declares Quarterly Preferred Stock Dividend... (more)
Legal & Copyright Disclaimer. © Copyright 2008 Mylan Inc. All rights reserved. Privacy Policy.